Omnicell (NASDAQ:OMCL) Stock Price Expected to Rise, Craig Hallum Analyst Says

Omnicell (NASDAQ:OMCL) had its target price raised by research analysts at Craig Hallum from $45.00 to $64.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Craig Hallum’s price objective would suggest a potential upside of 31.50% from the company’s current price.

A number of other analysts have also commented on the company. JPMorgan Chase & Co. boosted their price objective on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Benchmark reissued a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and upped their target price for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Wells Fargo & Company upped their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Finally, StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a report on Saturday, October 19th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Omnicell currently has an average rating of “Hold” and a consensus target price of $49.14.

Omnicell Stock Up 0.1 %

OMCL stock opened at $48.67 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 1.05. The stock’s 50 day simple moving average is $43.34 and its 200 day simple moving average is $35.32. The company has a market cap of $2.24 billion, a P/E ratio of -124.79, a price-to-earnings-growth ratio of 58.48 and a beta of 0.83. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.74.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. The firm had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. The company’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.29 EPS. On average, research analysts expect that Omnicell will post 0.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Omnicell by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after purchasing an additional 80,312 shares during the period. Pacer Advisors Inc. lifted its position in shares of Omnicell by 32.6% during the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after acquiring an additional 508,789 shares in the last quarter. Champlain Investment Partners LLC lifted its position in shares of Omnicell by 16.0% during the first quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after acquiring an additional 241,235 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Omnicell by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after acquiring an additional 3,570 shares in the last quarter. Finally, Federated Hermes Inc. lifted its position in shares of Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after acquiring an additional 909,480 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.